Crossmark

Forecasting the effectiveness of the DeWorm3 trial in interrupting the transmission of soil-transmitted helminths in three study sites in Benin, India and Malawi

Crossref DOI link: https://doi.org/10.1186/s13071-020-04572-7

Published Online: 2021-01-20

Published Print: 2021-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Truscott, James E. https://orcid.org/0000-0002-2555-7636
Hardwick, Robert J.

Werkman, Marleen

Saravanakumar, Puthupalayam Kaliappan

Manuel, Malathi

Ajjampur, Sitara S. R.

Ásbjörnsdóttir, Kristjana H.

Khumbo, Kalua

Witek-McManus, Stefan

Simwanza, James

Cottrell, Gilles

Houngbégnon, Parfait

Ibikounlé, Moudachirou

Walson, Judd L.

Anderson, Roy M.
Funding

Funding for this research was provided by:

Bill and Melinda Gates Foundation (OPP1129535)
License Information

Text and Data Mining valid from 2021-01-20

Version of Record valid from 2021-01-20
More Information

Article History

Received: 7 August 2020

Accepted: 29 December 2020

First Online: 20 January 2021

Ethics approval and consent to participate

: The DeWorm3 Project has been reviewed and approved by the Institut de Recherche Clinique au Benin (IRCB) through the National Ethics Committee for Health Research (002-2017/ CNERS-MS) from the Ministry of Health in Benin, The London School of Hygiene and Tropical Medicine (12013), The College of Medicine Research Ethics Committee (P.04/17/2161) in Malawi and the Christian Medical College Institutional Review Board in Vellore, India (10392). The study was also approved by The Human Subjects Division at the University of Washington (STUDY00000180).

: Not applicable.

: The authors declare that they have no competing interests.

Document is current

Any future updates will be listed below